Can tirzepatide help with obstructive sleep apnoea and obesity together?

Why does losing weight improve sleep apnoea in the first place?

Obstructive sleep apnoea happens when soft tissue around the throat relaxes and narrows the airway during sleep, causing repeated pauses in breathing. Excess adipose tissue, especially around the neck and upper chest, makes that narrowing worse. The connection is well-established: higher BMI is one of the strongest predictors of OSA severity. So when a medicine produces substantial, sustained weight reduction, the airway mechanics tend to follow.

Tirzepatide's trials have made that link unusually visible. The SURMOUNT-OSA programme enrolled adults with moderate-to-severe OSA alongside obesity. At 52 weeks, AHI scores, the standard measure of breathing interruptions per hour of sleep, fell by around 55% in participants who were not using CPAP therapy, and by around 63% in those who were using it alongside tirzepatide. Those figures come from a programme that tirzepatide's treatment profile situates within the wider SURMOUNT evidence base, which also showed average body-weight reductions of roughly 20% at the highest dose in the obesity trials. Sleep apnoea improvement tracked closely with weight loss across participants, reinforcing the idea that the airway benefit is mostly downstream of the metabolic one.

That does not make it any less real. Less interrupted sleep affects energy levels, cardiovascular risk, blood pressure, and mood in ways that compound over time. For people managing OSA, it matters.

Does tirzepatide actually treat sleep apnoea, or just the obesity behind it?

This is the question most people have, and the honest answer is: both, inseparably. Tirzepatide does not act directly on the muscles or tissues of the upper airway. Its licensed indication in the UK is weight management, not OSA treatment as a standalone condition. The NICE appraisal of tirzepatide (NICE TA1026) covers adults with a BMI of 35 or above and at least one weight-related comorbidity; OSA is explicitly among the qualifying conditions.

So the practical picture is this: if you have OSA because of excess weight, and tirzepatide helps you lose a meaningful amount of that weight, your sleep apnoea is very likely to improve as a consequence. Some people in the trials saw enough improvement to reduce their reliance on CPAP machines; a smaller number no longer met the diagnostic threshold for OSA at all. Those outcomes are not guaranteed, and a prescriber will want to understand your full history, including whether OSA has another structural cause that weight loss alone will not resolve.

There is also good reason to look at the full range of conditions tirzepatide can address when building a picture of whether it suits your situation. OSA, hypertension, dyslipidaemia and type 2 diabetes often coexist in the same person, and the weight-loss evidence covers all of them.

What does the eligibility picture look like for someone with OSA and obesity?

For private treatment, the licensed threshold is a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. OSA qualifies as that condition, so someone with a BMI just above 27 and a confirmed OSA diagnosis would meet the licence criteria on paper. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of that replaces a clinical assessment: a prescriber looks at the full picture, including any medicines you already take, relevant medical history, and whether OSA is controlled or active, before approving treatment.

On the NHS, tirzepatide is being rolled out in phases under NICE TA1026. Eligibility currently requires a BMI of 40 or above alongside four or more of the qualifying comorbidities; OSA is on that list. Criteria are widening gradually, but NHS waiting times and availability vary by area. Many people turn to a regulated private route because they do not yet qualify for the NHS cohort or prefer not to wait. If cost is part of your thinking, the Mounjaro pricing page sets out what private treatment actually covers.

The NHS England page on weight management injections is the clearest current source on NHS phasing and what wrap-around lifestyle support is required alongside the medicine.

What else should someone with sleep apnoea think about when starting tirzepatide?

A few practical things are worth raising with your prescriber before starting. If you use CPAP, continue using it unless a sleep specialist has told you otherwise; tirzepatide's benefits take weeks to months to accumulate, and stopping CPAP prematurely risks a difficult period. It is also worth flagging your OSA status when you fill out your consultation, so the prescriber has a complete picture.

Diet matters alongside the medicine. Tirzepatide slows gastric emptying, which means food sits in the stomach longer, and some people find large meals in the evening make both GI side effects and sleep harder. Smaller, earlier evening meals tend to work better, a detail the eating-on-tirzepatide guide covers in depth, including the protein-first approach that helps preserve muscle during weight loss.

Some people notice improved energy and daytime alertness within weeks of starting treatment, even before significant weight comes off; better sleep architecture from fewer apnoeas may be contributing. Others find the GI side effects in the early weeks affect their sleep instead. Nausea, which is most common after starting or after a dose step, usually settles within a couple of weeks. If it does not, that is a conversation for your prescriber, not something to push through alone. Our frequently asked questions cover a lot of the practical day-to-day detail people ask about once they begin.

One thing patients sometimes ask about: timing of orders around public holidays. If you are planning to start treatment or move to a new dose, it is worth factoring in that same-day dispatch requires ordering before 12pm on a working day, and bank holiday periods can affect next-working-day delivery windows. Worth a moment's thought if you are planning around Christmas or Easter.

Mounjaro, the brand name under which tirzepatide is sold in the UK, is dispensed through a clearly described process, and reading about how Mounjaro treatment works is a useful step before deciding whether to go ahead. If you are interested in whether you are a suitable candidate, the right starting point is a clinical assessment rather than a product page, and our guide to Mounjaro treatment for weight loss explains what that process involves and what you can reasonably expect from it.